Themed "Global IVD Innovation & Cross-Regional Integration," this groundbreaking event brings together distinguished experts from around the world to explore the future of diagnostics.

Recently, South Korean idol Song Joong Ki endorsed SD BIOSENSOR, an in vitro diagnostic company, sparking heated discussions in the IVD industry.

To date, no immunological data on COVID-19 heterologous vaccination schedules in humans have been reported. We assessed the immunogenicity and reactogenicity of BNT162b2 (Comirnaty, BioNTech, Germany) administered as second dose in participants primed with ChAdOx1-S (Vaxzevria, AstraZeneca, UK).

On June 21st, COVID-19 Antigen Rapid Test (Colloidal Gold) COVID-19 Antigen Schnelltest (kolloidales Gold) Probe: Speichel (Spucktest) developed by Joinstar Biomedical Technology obtained the approval of the German Federal Agency for Medicines and Medical Devices to enter the self-testing list.

On June 26, 2021, Shanghai, Sanyou Biopharmaceutical (Shanghai) Co., Ltd. announced the closing of series B financing. This financing round was co-led by LH Ventures and Montesy Investment and followed by Grand Mount Capital and Seeking Capital (an existing investor).

Jun. 22, 2021– PerkinElmer, Inc. (NYSE: PKI) (“PerkinElmer”) is pleased to announce it has entered into an agreement to acquire SIRION Biotech GmbH, a leading, global provider of viral vector. The acquisition is expected to close during the third quarter of 2021.

On June 23, 2021, Suzhou Nanomicro Technology Co., Ltd. was listed on SSE STAR Market. Stock code: 688690. The number of A shares publicly issued this time is 44 million shares, the issue price is 8.07 yuan/share, and the opening price is 93.00 yuan/share.

On the evening of June 21st, Sansure acquired a 14.77% equity interest in GeneMind through equity transfer and subscription of newly added registered capital at a cost of RMB 255.2 million. When the transaction is completed, Sansure will become the second largest shareholder of GeneMind.

JP Morgan and Cowen said on Monday they have initiated coverage of shares of Singular Genomics Systems.JP Morgan gave the shares an Overweight rating and a price target of $30 while Cowen gave them an Outperform rating.

Roche announced recently that its RT-PCR-based Cobas SARS-CoV-2 nucleic acid test for use on the Cobas Liat system has received Emergency Use Authorization from the US Food and Drug Administration.

A new antibody testing study examining samples originally collected through the National Institutes of Health’s All of Us Research Program found evidence of SARS-CoV-2 infections in five states earlier than had initially been reported.